Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

Michael E O'Dwyer, MD, FRCPI, FRCPath, Ronan Swords, MD, MRCPI, FRCPath, Francis Giles, MD FRCPI FRCPath, Mary Frances McMullin, MD, Philipp D. le Coutre, MD, Arnon Nagler, Stephen Langabeer, Marzena Wieczorkowska, Cliona McDowell, Karine Egan, Brian Moulton, Eibhlin Conneally, MB, MRCPI, FRCPath, PhD

Blood (2011) 118 (21): 3774.

https://doi.org/10.1182/blood.V118.21.3774.3774

Published: 2011

Journal Articles

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Jean-Marie Bruey, Hagop M. Kantarjian, MD, Wanlong Ma, Chen-Hsiung Yeh, Tai-Sung Lee, Susan O'Brien, Francis Giles, MD, Zeev Estrov, MD, Jorge Cortes-Franco, MD, Maher Albitar, MD

Blood (2009) 114 (22): 2179.

https://doi.org/10.1182/blood.V114.22.2179.2179

Published: 2009

Journal Articles

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

Susan O’Brien, M.D., Gary Schiller, Robert Kenneth Stuart, MD, Diana Hudak, Francis Giles, MD

Blood (2008) 112 (11): 940.

https://doi.org/10.1182/blood.V112.11.940.940

Published: 2008

Journal Articles

A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies.

Susan O’Brien, M.D., David A. Rizzieri, MD, Norbert Vey, MD, Hagop M Kantarjian, Tove Flem Jacobsen, Bo I Nilsson, MD, PhD, Karin Staudacher, Francis Giles, MD

Blood (2008) 112 (11): 949.

https://doi.org/10.1182/blood.V112.11.949.949

Published: 2008

Journal Articles

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

Elias Jabbour, MD, Hagop M Kantarjian, Michele Baccarani, MD, Philipp D. le Coutre, MD, Ariful Haque, Neil J. Gallagher, MD, PhD, Jorge Cortes, MD, Francis Giles, MD

Blood (2008) 112 (11): 3215.

https://doi.org/10.1182/blood.V112.11.3215.3215

Published: 2008

Journal Articles

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Robert Hills, MA, MSc, DPhil, Susan O’Brien, M.D., Verena Karsten, PhD, Alan K. Burnett, MD, FRCP, Francis Giles, MD

Blood (2008) 112 (11): 2960.

https://doi.org/10.1182/blood.V112.11.2960.2960

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Philipp D. le Coutre, MD, Francis Giles, MD, Andreas Hochhaus, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Gert Ossenkoppele, MD, PhD, Ariful Haque, Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Jorge Cortes, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3229.

https://doi.org/10.1182/blood.V112.11.3229.3229

Published: 2008

Journal Articles

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Jeffrey H. Lipton, MD, PhD, Philipp D. le Coutre, MD, Jim Wang, PhD, Mindy Yang, PharmD, Tomasz Szczudlo, MD, Francis Giles, MD

Blood (2008) 112 (11): 3233.

https://doi.org/10.1182/blood.V112.11.3233.3233

Published: 2008

Journal Articles

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Francis Giles, MD, Philipp D. le Coutre, MD, Kapil N. Bhalla, MD, Gert J Ossenkoppele, MD, PhD, Giuliana Alimena, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Hagop M Kantarjian

Blood (2008) 112 (11): 3234.

https://doi.org/10.1182/blood.V112.11.3234.3234

Published: 2008

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Hagop M Kantarjian, Francis Giles, MD, Kapil N. Bhalla, MD, Richard A. Larson, MD, Norbert Gattermann, MD, Oliver G. Ottmann, MD, Ariful Haque, M.S., Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2008) 112 (11): 3238.

https://doi.org/10.1182/blood.V112.11.3238.3238

Published: 2008

Journal Articles

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Ilan Bernstein, MD, Francis Giles, MD, Susan O’Brien, MD, Elizabeth Sullivan, MS, Norbert Vey, MD, Allen S. Yang, MD, PhD

Blood (2008) 112 (11): 4463.

https://doi.org/10.1182/blood.V112.11.4463.4463

Published: 2008

Journal Articles

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Oliver G. Ottmann, MD, Richard A. Larson, MD, Hagop M. Kantarjian, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Ariful Haque, Neil Gallagher, Francis Giles, MD

Blood (2007) 110 (11): 2815.

https://doi.org/10.1182/blood.V110.11.2815.2815

Published: 2007

Journal Articles

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Jorge Cortes, MD, Elias Jabbour, MD, Andreas Hochhaus, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Francis Giles, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1040.

https://doi.org/10.1182/blood.V110.11.1040.1040

Published: 2007

Journal Articles

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Gautam Borthakur, MD, Farhad Ravandi, MD, Susan O’Brien, MD, Miloslav Beran, MD, Betsy Williams, RN, Howard Goldsweig, MD, Francis Giles, MD

Blood (2007) 110 (11): 1600.

https://doi.org/10.1182/blood.V110.11.1600.1600

Published: 2007

Journal Articles

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

Farhad Ravandi, MD, Jeffrey Lancet, MD, Francis Giles, MD, William Plunkett, PhD, Betsy Williams, RN, Michelle Burton, RN, Stefan Faderl, MD, Zeev Estrov, MD, Gautam Borthakur, MD, Lawrence Akinsanmi, MD, Hagop Kantarjian, MD

Blood (2007) 110 (11): 913.

https://doi.org/10.1182/blood.V110.11.913.913

Published: 2007

Journal Articles

A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.

Francis Giles, MD, Hagop M. Kantarjian, MD, Norbert Vey, MD, David Rizzieri, MD, Farhad Ravandi, MD, Thomas Prebet, MD, Tove Flem Jacobsen, Bo I. Nilsson, MDPhD, Karin Staudacher, Susan O’Brien, MD

Blood (2007) 110 (11): 901.

https://doi.org/10.1182/blood.V110.11.901.901

Published: 2007

Journal Articles

Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.

Annelie Abrahamsson, MS, Ifat Geron, MS, Jason Gotlib, MD MS, Kim-Hien Dao, DO PhD, Francis Giles, MD, Isabel Newton, MD PhD, Edward Kavalerchik, MD, Jeffrey Durocher, PhD, Remi Creusot, PhD, Mobin Karimi, PhD, Carol Jones, PhD, James Zehnder, PhD, Armand Keating, MD, Robert Negrin, MD, Irving L. Weissman, MD, Catriona H.M. Jamieson, MD PhD

Blood (2007) 110 (11): 775.

https://doi.org/10.1182/blood.V110.11.775.775

Published: 2007

Journal Articles

Novel Tyrosine Kinase Inhibitor Therapy (NTKI) Prior to Allogeneic Stem Cell Transplantation (ASCT) in Patients with Chronic Myeloid Leukemia (CML): No Evidence for Increased Transplant-Related Toxicity.

Elias Jabbour, MD, Jorge Cortes, MD, Hagop Kantarjian, MD, Sergio Giralt, MD, Francis Giles, MD, Borje S. Andersson, MD, Richard Champlin, MD, Marcos de Lima, MD

Blood (2006) 108 (11): 5262.

https://doi.org/10.1182/blood.V108.11.5262.5262

Published: 2006

Journal Articles

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

Francis Giles, MD, Jorge Cortes, MD, Donald A. Bergstrom, MD, PhD, Alan Xiao, PhD, Dan Jones, MD, PhD, Srdan Verstovsek, MD, PhD, Deborah Thomas, MD, Hagop M. Kantarjian, MD, Steven J. Freedman, MD, PhD

Blood (2006) 108 (11): 253.

https://doi.org/10.1182/blood.V108.11.253.253

Published: 2006

Journal Articles

The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS).

Hagop M. Kantarjian, MD, Francis Giles, MD, FRCPI, FRCPath, Alan F. List, MD, Roger Lyons, MD, Sherry Price, BSN, Robert Deuson, PhD, Joseph Leveque, MD

Blood (2006) 108 (11): 2617.

https://doi.org/10.1182/blood.V108.11.2617.2617

Published: 2006

NARROW

Analysis of the GeneXpert System on the International Multicentre ICORG 08–02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML),

A Common but Overlooked Mechanism of BCR-ABL1 Kinase Inhibitor Resistance in Chronic Myeloid Leukemia.

Survival after Complete Response to Treatment with Laromustine (CLORETAZINE ® ) in Elderly Patients with De Novo Poor Risk Acute Myelogenous Leukemia (AML).

A Phase I/II Study with CP-4055 in Patients with Haematologic Malignancies.

Minimal Cross-Intolerance Between Nilotinib and Imatinib in Patients with Imatinib-Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) or Accelerated Phase (CML-AP)

A Retrospective Comparison of Matched Elderly Patients Treated with Laromustine (Cloretazine®) or Best Supportive Care or Low Dose Ara-C in the LRF AML14 Trial

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis

Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study

Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study.

Hypermethylation of O 6 -Methylguanine-DNA Methyltransferase (MGMT) Predicts Response to Laromustine (Cloretazine®) in Patients with Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Nilotinib in Patients (pts) with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Who Are Resistant or Intolerant to Imatinib.

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Phase I Study of S-trans, Trans-farnesylthiosalicylic Acid (FTS), a Novel Oral Ras Inhibitor, in Patients with Refractory Hematologic Malignancies.

Phase I Study of Triciribine Phosphate Monohydrate, a Specific Inhibitor of AKt Phosphorylation, in Adult Patients with Advanced Hematologic Malignancies.

A Phase I Study with CP-4055 In Patients with Hematologic Malignancies.

Missplicing of Glycogen Synthase Kinase 3β: A Potential Mechanism of Blast Crisis Chronic Myeloid Leukemia Stem Cell Generation.

Novel Tyrosine Kinase Inhibitor Therapy (NTKI) Prior to Allogeneic Stem Cell Transplantation (ASCT) in Patients with Chronic Myeloid Leukemia (CML): No Evidence for Increased Transplant-Related Toxicity.

MK-0457, a Novel Multikinase Inhibitor, Is Active in Patients with Chronic Myeloid Leukemia (CML) and Acute Lymphocytic Leukemia (ALL) with the T315I BCR-ABL Resistance Mutation and Patients with Refractory JAK-2 Positive Myeloproliferative Diseases (MPD).

The Incidence and Impact of Thrombocytopenia in Myelodysplastic Syndrome (MDS).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only